CA-HVR-SOFTWARE
Market leading, real-time data replication is now available to Microsoft Azure customers. Following growing demand, HVR Software , provider of real-time data integration technology in heterogeneous environments, today announced the availability of HVR for Azure in the Azure Marketplace . This move will enable more companies to shift toward modern data architecture while keeping their data synced in real-time, whether in on-premise or cloud environments. Microsoft Azure customers can currently receive a free one-month trial of HVR for Azure when using the service for the first time.
“We are pleased to bring our market-leading real-time data integration capabilities to the Microsoft Azure platform. Our support for Azure is yet another step in giving our customers the flexibility to migrate to, or bridge, the world of on-premise and cloud,” said Anthony Brooks-Williams , CEO of HVR.
With HVR for Azure, companies can be confident that their data is in sync, secure, and where they need it. It allows companies to perform zero-downtime migrations, validate consistency between on-premise and cloud data sets, as well as provide a fail-back to on-premise without losing cloud transactions. The new release also includes auto-email notifications and SNMP alerts, and real-time monitoring of data movement.
Richard Kramer, Platform Architect at PostNL , a mail, parcel and e-commerce corporation based in the Netherlands, said of HVR for Azure: “HVR made it easy for us to migrate dozens of mission critical applications and databases to Azure. Without HVR, we would have been forced to plan big bang migrations with unacceptable impact on the continuity of our core business processes…HVR gives us the flexibility of running applications where we want, with HVR solving all connectivity issues at low cost.”
New users can easily implement the software to start benefiting immediately. All necessary components are included to connect to Azure SQL, Microsoft SQL Server, Oracle, and much more, enabling replication from and into all supported on-premise platforms. With a few clicks, the Azure platform is ready to receive or send data through HVR.
About HVR
HVR Software is a leading provider of real-time data replication and is proven as the reliable, secure, and scalable way to move data for many of the world’s largest companies. HVR provides real-time heterogeneous data replication software across platforms including Azure and SQL Server and is the only complete data replication solution that offers schema creation, initial data load, real-time change data capture and delivery, and compare/repair.
HVR Software is a privately held company based in San Francisco, with offices across North America, Europe, and Asia.
About PostNL
We are PostNL . For our clients, we are the link between the physical and the online world. We facilitate communications between people and companies. On average, we deliver 550,000 parcels and 10 million letters a day throughout all of the Netherlands. We offer more and more new services through combinations of smart networks, digital applications, and the right communications channels. In doing so, we aim to make the daily lives of our customers easier.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161026006684/en/
Contact:
HVR Software
Meredith Stowe Christie
meredith.christie@hvr-software.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom